Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Nature Medicine 13, 272-273 (1 March 2007) | doi:10.1038/nm0307-272;
News feature: Trials and tribulations
Abstract
Salim Karim has a rare problem: he has a large grant from the US National Institutes of Health (NIH) that he doesn't want. In 2001 Karim, who leads Caprisa, a South Africa-based consortium of AIDS and TB researchers, applied for a grant to try to pin down how best to stagger treatments for tuberculosis and HIV in those infected with both.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
